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ABSTRACT
Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced
cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the
“cancer-immunity cycle” in the pan-cancer setting in order to understand the immune landscape of
metastatic malignancies as well as anti-PD-1/PD-L1 inhibitor resistance mechanisms. Interrogation of 51
markers of the cancer-immunity cycle was performed in 101 patients with diverse malignancies using
a clinical-grade RNA sequencing assay. Overall, the immune phenotypes demonstrated overexpression of
multiple checkpoints including VISTA (15.8% of 101 patients), PD-L2 (10.9%), TIM3 (9.9%), LAG3 (8.9%), PD-L1
(6.9%) and CTLA4 (3.0%). Additionally, aberrant expression of macrophage-associated markers (e.g. CD68
and CSF1R; 11-23%), metabolic immune escapemarkers (e.g. ADORA2A and IDO1; 9-16%) and T-cell priming
markers (e.g. CD40, GITR, ICOS and OX40; 4-31%) were observed. Most tumors (87.1%, 88/101) expressed
distinct immune portfolios, with a median of six theoretically actionable biomarkers (pharmacologically
tractable by Food and Drug Administration approved agents [on- or off-label] or with agents in clinical
development). Overexpression of TIM-3, VISTA and CD68 were significantly associated with shorter progres-
sion-free survival (PFS) after anti-PD-1/PD-L1-based therapies (among 39 treated patients) (all P < .01). In
conclusion, cancer-immunity cycle biomarker evaluation was feasible in diverse solid tumors. High expres-
sion of alternative checkpoints TIM-3 and VISTA and of the macrophage-associated markers CD68 were
associatedwith significantly worse PFS after anti-PD-1/PD-L1-based therapies.Most patients had distinct and
complex immune expression profiles suggesting the need for customized combinations of immunotherapy.
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Introduction
Immunotherapies, including vaccine therapy, chimeric antigen
receptor (CAR) T-cell therapy and immune checkpoint inhibi-
tors (ICIs) have evolved rapidly in recent years as a consequence
of our accumulating understanding of tumor immunity1 Among
these, ICIs, such as monoclonal antibodies against cytotoxic
T lymphocyte antigen-4 (CTLA-4) and programmed death-1
(PD-1) or programmed death ligand-1 (PD-L1), are some of
the most successful examples of drug development and, conse-
quently, immune therapy has become standard of care in diverse
malignancies.2 Indeed, ICIs have been reported to exhibit anti-
tumor effects against a wide range of tumor types, including both
solid and hematological malignancies.3–7
However, ICIs are effective in only a portion of patients
(response rates ranging from <5% to >40%, depending on the
cancer type). Further, many patients exhibit serious side effects
and somemay also show accelerated disease progression (known
as hyperprogression).8 Thus, there is an unmet need to
understand the biomarkers associated with anti-tumor immune
effects in individual patients. To date, several markers have been
identified as predictors of response to ICIs including, but not
limited to; (i) high PD-L1 expression or amplification,9,10
(ii) microsatellite instability)- high (MSI-H)11 or deficiency in
mismatch repair genes,12 (iv) presence of tumor infiltrating
lymphocytes (TILs)13 and (v) high tumor mutation burden
(TMB).14 However, even in the presence of the aforementioned
biomarkers, not all patients demonstrate response to ICIs.15–17
To further enhance the anti-cancer effect with ICIs, deeper
interrogation of the immune tumor milieu is warranted. This
issue is also relevant to the many clinical trials combining ICIs
with other therapeutic modalities, such as chemotherapy, mole-
cularly targeted drugs, radiotherapy, or with various immune
modulators.18–20 Although there are signals of improved anti-
tumor effect with some combination approaches,21–24 in large,
preliminary results suggest that optimization of combinations is
still needed. For example, epacadostat, an IDO1 inhibitor,
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showed promising results in a phase II trial; however, a pivotal
phase III trial in advanced melanoma failed to demonstrate
superiority with the addition of epacadostat to pembrolizumab
when compared to pembrolizumab alone (ECHO-301/Keynote-
252 study).22 Moreover, the clinical efficacy of combinations of
ipilimumab plus nivolumab when compared to nivolumab alone
in patients advanced melanoma appears similar (overall survival
[OS] rate at 3 years of 58% in the ipilimumab-plus-nivolumab
group vs. 52% in the nivolumab group).24
In the field of genomics, there are several remarkable suc-
cesses with the use of targeted drugs. The most striking response
rates occur when patients with specific genomic alterations are
selected to receive cognate antagonists: imatinib for the treat-
ment of chronic myelogenous leukemia harboring BCR-ABL
fusion gene,25 anti-EGFR therapies (e.g. gefitinib, erlotinib, osi-
mertinib) for epidermal growth factor receptor (EGFR)-mutant
lung cancer,26 and crizotinib for anaplastic lymphoma kinase
(ALK)-mutant lung cancer.27 Hence the key to success is choos-
ing the right patient for the right drug based on matched
biomarkers.28–32 These results have been confirmed by meta-
analyses of large datasets, including meta-analyses of 346 pub-
lished phase I trials showed that a personalized (biomarker
matched) strategy using genomic biomarkers was associated
with significantly higher response rates compared with a non-
matched approach (response rate, 42% vs. 5%; p < .001)30
Although anti-CTLA-4 inhibitors and anti-PD-1 or anti-
PD-L1 inhibitors already have remarkable effects in
a subgroup of patients, many patients still do not respond
to these drugs. To enhance patient selection, especially for
combination therapies, comprehensive understanding of the
cancer immunogram landscape is imperative.33 Each step in
the cancer-immunity cycle is regulated by various stimula-
tory and inhibitory factors that can potentially be targets of
interest to optimize the anti-cancer immune effect
(Supplemental Table 1). It is conceivable that, as is the case
with matching therapy to genomic targets, matching
immune modulators to the individual patient immune land-
scape may optimize salutary effects. Therefore, in order to
facilitate rational clinical trial development, and better
understand response and resistance, we comprehensively
analyzed pan-cancer immunity markers.
Results
Patient characteristics
Among 101 patients with diverse malignancies, the median age
was 57.1 years (range: 24.6–87.1 years), and 61.4% (62/101) were
women. Themost common diagnosis was gastrointestinal cancers
(non-colorectal, 30.7% [31/101] and colorectal cancers, 20.8% [21/
101]), followed by gynecologic cancers (15.8% [16/101]) (Table 1).
Among 101 patients, 39 patients received anti-PD-1/PD-L1 based
regimens.
A variety of patterns of RNA expression level for immune
markers were seen in patients with cancer (N = 101)
A variety of immune response markers were evaluated (N = 51
markers) and RNA expression was ranked on a scale of 1 to
100 and stratified into “Very high” (95–100), “High” (85–94),
“Moderate” (50–84), “Low” (20–49), and “Very Low” (0–19)
based on an internal reference population34 Among checkpoint
markers, high or very high RNA expression were most com-
monly observed in VISTA (15.8% [16/101 of patients]) fol-
lowed by PD-L2 (10.9% [11/101]), TIM3 (9.9% [10/101]),
LAG3 (8.9% [9/101]) and PD-L1 (6.9% [7/101]). High/very
high RNA expression in macrophage-associated markers
(some of which are myeloid suppressors) were most commonly
seen in CSF1R (22.8% [23/101]), CCR2 (13.9% [14/101]) and
CD163 (12.9% [13/101]). Among metabolic immune escape
markers, RNA was highly expressed in CD39 (15.8% [16/
101]), IDO1 (12.9% [13/101]) and ADORA2A (8.9% [9/101]).
T-cell primed markers were most commonly expressed among
OX40 ligand (30.7% [31/101]) followed by ICOS ligand (25.7%
[26/101]), CD86 (18.8% [19/101]), CD80 (12.9% [13/101]),
GZMB (12.9% [13/101]) and GITR (11.9% [12/101]). Several
pro-inflammatory response markers were highly expressed in
IL1B (34.7% [35/101]), DDX58 (32.7% [33/101]) and MX1
(24.8% [25/101]). Lastly, among tumor infiltrating lymphocyte
markers, high/very high RNA expression were seen among
CD4 (18.8% [19/101]), FOXP3 (17.8% [18/101]) and
KLRD1 (11.9% [12/101]) (Figure 1, Supplemental Table 2 and
Supplemental Figure 1).
Most patients had potentially actionable cancer-
immunity markers (N = 101)
Overall, 52.5% (N = 53) of the 101 patients had at least one
cancer-immunity cycle associated biomarker which was theo-
retically actionable by an FDA-approved agent (on- or off-
label). Additionally, 46.5% (N = 47) had at least one cancer-
immunity biomarker which was potentially targetable with an
agent that is in clinical investigation (Figure 2 and
Supplemental Table 1). Altogether, 99.0% (N = 100) of the
patients had at least one theoretically actionable biomarker
either with agents that are approved by the Food and Drug
Administration (FDA) (on- or off-label) or with agents that
are in clinical trials. The median number of actionable
Table 1. Patient characteristics (N = 101).
Basic characteristics (N = 101) N (%)
Age, median (range) (years) 57.1 (24.6–87.1)
Sex, N (%)
Women 62 (61.4%)
Men 39 (38.6%)
Ethnicity, N (%)
Caucasian 64 (63.4%)
Asian 16 (15.8%)
Hispanic 11 (10.9%)
African American 3 (3.0%)
Other 7 (6.9%)
Types of cancer diagnosis, N (%)
Gastrointestinal, non-colorectal 31 (30.7%)
Gastrointestinal, colorectal 21 (20.8%)
Gynecologic 16 (15.8%)
Lung, non-small cell 7 (6.9%)
Breast 7 (6.9%)
Head, neck and thyroid 5 (5.0%)
Skin/melanoma 3 (3.0%)
Other * 11 (10.9%)
*Other: Includes patients with sarcoma (N = 4), adrenocortical carcinoma (N = 3),
carcinoma of unknown primary (N = 2), prostate cancer (N = 1), and mesothe-
lioma (N = 1).
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biomarkers that were associated with the cancer-immunity
cycle was 6 (per patient) (range, 0–16).
Most patients had distinct expression patterns of cancer-
immunity markers (N = 101)
Among the 101 patients, most patients (87.1% [88/101]) had
different expression patterns of cancer-immunity markers
(Figure 2). Four patients had high/very high RNA expression
only in IL1B; three had high/very high RNA expression in
both DDX58 and MX1; and six did not have highly expressed
RNA in any of the cancer-immunity markers evaluated
(Figure 2).
Patients with colorectal cancer had higher expression of
IL-1B (inflammatory cytokine) than non-colorectal cancer
We examined the expression patterns of cancer-immunity
markers between colorectal cancer (N = 21) and non-
colorectal cancers (N = 80) and found that CCR2 (receptor
for the CCL2; mediates signaling for chemotaxis) and GATA3
(highly expressed in helper T cells) were highly expressed
among patients with non-colorectal cancers (high expression
of CCR2 and GATA3 in colorectal vs. non-colorectal: 0%
[0/21] vs. 17.5% [14/80], P = .038) (Supplemental Table 3).
In contrast, high expression of IL1B was more commonly seen
among patients with colorectal cancer (57.1% [12/21] vs.
28.7% [23/80], P = .021) (Supplemental Table 3). Moreover,
Figure 1. Frequency of high/very high RNA expression among cancer-immunity markers (N=101).
Among diverse cancer immunity markers evaluated, IL1B was most commonly highly expressed (34.7%) followed by DDX58 (32.7%), OX40 ligand (30.7%), ICOS
ligand (25.7%) and TGFB1 (25.7%).
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patients with gynecological cancers appear to have numeri-
cally higher frequencies of certain cancer-immunity markers
when compared to other disease types including high expres-
sion of LAG3 (25%), GZMB (25%), IDO1 (31.3%), IL10
(43.8%) and OX40 ligand (62.5%) (though this did not reach
statistical significance) (Supplemental Table 3).
High RNA expression in checkpoint markers TIM3 and
VISTA as well as macrophage-associated markers CD68
as potential resistant markers for anti-PD-1/PD-L1 based
regimens (N = 39)
Among 101 patients analyzed in this study, 39 received anti-PD-
1/PD-L1 based regimens and were evaluated for progression-
free survival (PFS) (Table 2). Among diverse cancer-immunity
markers, high expression of TIM3 (P = .007), VISTA (P = .001),
and CD68 (P = .009) were significantly associated with shorter
PFS (median 1.7 versus 5.9 months in each case) (Table 3 and
Supplemental Table 4) and were retained after the Bonferroni
correction for multiple comparisons.
Among 39 patients who received anti-PD-1/PD-L1 based
immunotherapy, 32 patients were evaluable for response.
Clinical benefit was defined as achieving stable disease (SD)
≥ 6 months, partial response (PR) or complete response (CR).
High expression of TIM3 and VISTA showed a trend toward
lower rates of SD ≥6 months/PR/CR (0 versus 52% in each
case; p = .052) as did CD68 (albeit weaker; 0 versus 50%;
p = .113) (Table 4). The small number of patients evaluable
for response may have limited the analysis.
Discussion
Although immunotherapies, especially checkpoint inhibitors,
have achieved some remarkable salutary anti-cancer effects
among patients with numerous advanced malignancies, only
a subgroup of patients respond to immunotherapies. Several
biomarkers have been demonstrated to correlate with
responsiveness.8–12,14 However, as new immunotherapy
agents have entered the clinical arena, a broader and more
robust spectrum of predictive markers is needed, especially for
combination treatments.20,35 Herein, we comprehensively
evaluated biomarkers associated with the “cancer-immunity
cycle” among patients with diverse advanced solid tumors.
Patients appeared to have a wide variety of immune markers
(Figure 2 and Supplemental Table 2). Along with the well-
known checkpoint marker PD-L1, some tumors had high
expression of other checkpoint markers (such as CTLA4
[3.0% of 101 patients had high expression], TIM3 [9.9%] and
VISTA [15.8%]) as well as other factors involved in the cancer-
immunity cycle including high expression of macrophage-
associated markers (such as CD68 [11.9%], CCR2 [13.9%]
and CSF1R [22.8%]), metabolic immune escape markers
(such as ADORA2A [8.9%] and IDO1 [12.9%]), and anti-
inflammatory immune markers (such as IL10 [20.8%])
(Figure 1, Supplemental Table 2 and Supplemental Figure 1).
Theoretically, patients harboring high expression of immune-
suppressive markers may benefit by targeting the specific inhi-
bitory markers (e.g. to selectively administer IDO1 inhibitor
among patients found to have high expression of IDO1)
(Supplemental Table 1). On the other hand, expression of
certain immune-stimulatory factors was low among patients
with diverse cancers (e.g., very low/low expression was seen in
ICOS ligand [38.6% of 101 patients]), CD40 ligand [53.5%] and
GITR [53.5%]). For those patients with low expression of
immune-stimulatory factors, it is conceivable that interven-
tions that enhance the stimulatory factor may have a higher
chance of demonstrating anti-cancer immune effects when
compared to giving such stimulators to patients who may
already have high endogenous expression of the molecule
(Supplemental Table 1).
Especially pertinent for the development of various immu-
notherapy agents was the observation that the immune envir-
onment differed from patient to patient. Indeed, most patients
(87.1%, 88/101) had distinct expression patterns of cancer-
immunity markers. This observation is comparable to that
reported in the cancer genomic field where the landscape of
genomic alterations is complex and differs between patients
even when they harbor tumors of the same histologic
diagnosis36 Admittedly, there are some pattern similarities
within histologies (in both the genomic portfolios patients
carry and, per our study, in the immune landscape of tumors).
For instance, patients with colorectal cancer appeared to have
higher expression of the inflammatory cytokine IL1B when
compared to non-colorectal cancer patients (Supplemental
Table 3). The high IL1B could conceivably be due to the fact
that KRAS alterations (common in colorectal cancer) have
Table 2. Characteristics of patients who were treated with anti-PD-1/PD-L1
based immunotherapy (N = 39).
Basic characteristics N (%)
Age, median (range) (years) 60.6 (31.6–87.1)
Sex, N (%)
Women 23 (59.0%)
Men 16 (41.0%)
Type of cancer, N (%)
Gastrointestinal, non-colorectal 11 (28.2%)
Gastrointestinal, colorectal 7 (17.9%)
Gynecologic 5 (12.8%)
Lung, non-small cell 5 (12.8%)
Head, neck and thyroid 3 (7.7%)
Skin/melanoma 3 (7.7%)
Breast 2 (5.1%)
Other * 3 (7.7%)
Anti-PD-1/PD-L1 based therapy administered as, N (%)
First line 9 (23.1%)
Second line 11 (28.2%)
Third line 10 (25.6%)
≥ Fourth line 9 (23.1%)
Type of immunotherapy, N (%)
Anti-PD-1/PD-L1 alone 13 (33.3%)
Anti-PD-1/PD-L1 with targeted agents 18 (46.2%)
Anti-PD-1/PD-L1 with chemotherapy 4 (10.3%)
Anti-PD-1/PD-L1 with anti-CTLA-4 3 (7.7%)
Anti-PD-1/PD-L1 with OX40 agonist 1 (2.6%)
Best response, N (%) (32 evaluable patients)
Complete response 1 (2.6%)
Partial response 5 (12.8%)
Stable disease ≥ 6 months 8 (20.5%)
Stable disease < 6 months 1 (2.6%)
Progressive disease 17 (43.6%)
Response assessment unavailable or too early to be
evaluated **
7 (17.9%)
*Other: Includes patients with sarcoma (N = 1); mesothelioma (N = 1); carcinoma
of unknown primary (N = 1).
**N = 4 had stable disease at the time of data cutoff, however, follow up was
less than 6 months and thus not included in the analysis. N = 3 without
adequate clinical information to assess the response.
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been previously shown to stimulate signal transduction path-
ways that activate the IL1B promoter37 Still, high IL1B was
not exclusive to colorectal cancer, and an immunoprint of our
patients (Figure 2) illustrates the diversity of immune portfo-
lios within and between histologies. Additionally, most
patients (99% [100/101]) had potentially targetable cancer-
immunity markers that were pharmacologically tractable
with either an FDA-approved agent (on- or off-label) or
with an agent that is in clinical investigation (median number
of potentially actionable immune biomarkers per patient: 6)
(Figure 2 and Supplemental Table 1). Taken together, these
findings suggest that the current standard of one-size-fits-all
approach for immunotherapy may not be ideal for optimizing
responsiveness and that obtaining an individualized immuno-
gram 38 and treating on that basis warrants exploration.
Although durable clinical response can be seen with ICIs in
a portion of patients, most patients do not demonstrate response
or unfortunately have a short duration of clinical responses.
Thus it is essential to understand the underlying biomarkers
that may predict both response and resistance. In addition to
known response markers (e.g. high TMB, MSI-high, deficiency
in mismatch repair genes and highPD-L1 expression or
amplification),9–12,14 several resistance markers for immune
therapy have also been reported: PTEN, STK11/LKB1 alterations
and activation of WNT/beta catenin for innate resistance mar-
kers, alterations in JAK2 or beta-2-microglobulin as an acquired
resistance, and EGFR and MDM2 alterations as potential mar-
kers for hyperprogression.8,39–42
In this regard, we examined immune markers that might
correlate with attenuated anti-PD-1/PD-L1 responsiveness
(Tables 3 and 4). Importantly, patients with high expression
of alternative checkpoints such as TIM-3 and VISTA, as well
as the macrophage-associated markers CD68, had signifi-
cantly shorter PFS (Table 3). TIM-3, also known as
Hepatitis A Virus Cellular Receptor 2 (HAVCR2), is a cell
surface receptor expressed on activated T cells. Binding of
C-type lectin galectin-9 (ligand of TIM-3) to TIM-3 leads to
an immune inhibitory signal.43 Further, TIM-3 upregulation
is associated with resistance to anti-PD-1 therapies in precli-
nical models44 Additionally, VISTA, also known as V-Set
Immunoregulatory Receptor (VSIR), is an immunoregulatory
receptor that inhibits the T-cell activation45 Among patients
with prostate cancer treated with ipilimumab (anti-CTLA-4
antibody), upregulation of VISTA was observed, suggesting
a compensatory inhibitor pathway as a resistance mechanism
after ipilimumab therapy46 Moreover, increased expression of
VISTA was seen among melanoma patients who progressed
on anti-PD-1 inhibitor therapy, also suggesting a role for
VISTA as an immune checkpoint47 Since TIM-3 and VISTA
were both implicated as resistant markers for anti-PD-1/PD-
L1 based immunotherapy in our dataset, targeting of TIM-3
and VISTA may be required to achieve a better clinical out-
come in selected patients. In the current study, high expres-
sion of CD68 was also significantly associated with poor PFS
after anti-PD-1/PD-L1 based immunotherapy (Table 3).
CD68 is a tumor-associated macrophage (TAM) marker that
can have pro-tumoral and immunosuppressive functions.
High TAM correlates with poor prognosis in breast cancer
and myxoid liposarcoma patients.48,49 In the preclinical set-
ting, TAM has been reported to play a key role in resistance to
Figure 2. Overview of mRNA expression level of multiple immune markers for each individual cases (N = 101).
Among 101 patients evaluated for cancer-immunity markers, most patients (87.1% [88/101]) had a unique expression pattern of cancer-immunity markers.
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anti-PD-1 therapy,50 which is in line with our current clinical
observations.
There were several limitations to our study. First, the sample
size was relatively small and was heterogeneous. Thus, further
Table 3. Association between immune markers and progression-free survival
among patients who received anti-PD-1/PD-L1 based regimens (N = 39).
Immune
phenotypes
Incidence of
High/Very high
(%)
Median PFS time (Very high/High
vs. Moderate/Low/Very low
biomarker expression *)
(Months) P-value **
Checkpoint markers
PD-1 1 (2.6%) 2.4 vs 4.4 0.423
PD-L1 3 (7.7%) 4.4 vs 2.7 0.335
PD-L2 6 (15.4%) 2.0 vs 5.9 0.229
Other Checkpoint markers
BTLA 0 (0.0%) - vs 4.4 -
CTLA-4 2 (5.1%) 4.4 vs 2.9 0.522
LAG3 3 (7.7%) 4.4 vs 2.9 0.638
TIM3 6 (15.4%) 1.7 vs 5.9 0.007 ***
VISTA 5 (12.8%) 1.7 vs 5.9 0.001 ***
TNFRSF14 0 (0.0%) - vs 4.4 -
Macrophage-associated markers
CCL2 8 (20.5%) 2.4 vs 5.9 0.096
CCR2 6 (15.4%) 1.7 vs 4.9 0.950
CD163 10 (25.6%) 2.7 vs 4.9 0.180
CD68 5 (12.8%) 1.7 vs 5.9 0.009 ***
CSF1R 11 (28.2%) 2.4 vs 5.9 0.127
Metabolic immune escape markers
ADORA2A 3 (7.7%) - vs 2.9 0.188
CD39 7 (17.9%) 2.7 vs 5.9 0.176
IDO1 4 (10.3%) 4.4 vs 2.9 0.911
Anti-inflammatory response markers
IL10 8 (20.5%) 2.0 vs 5.9 0.144
TGFB1 6 (15.4%) 1.7 vs 4.9 0.496
T-cell primed markers
CD137 4 (10.3%) 4.4 vs 2.9 0.984
CD27 1 (2.6%) 2.4 vs 4.4 0.423
CD28 4 (10.3%) 1.7 vs 4.9 0.018
CD40 2 (5.1%) 2.0 vs 4.4 0.726
CD40
ligand
1 (2.6%) 2.0 vs 4.4 0.271
GITR 6 (15.4%) 15.5 vs 2.9 0.268
ICOS 3 (7.7%) - vs 2.7 0.320
ICOS ligand 9 (23.1%) 2.7 vs 4.4 0.765
OX40 3 (7.7%) 20.6 vs 2.7 0.092
OX40
ligand
9 (23.1%) 2.4 vs 5.9 0.061
GZMB 5 (12.8%) 4.4 vs 2.9 0.740
IFNG 2 (5.1%) 4.4 vs 2.9 0.748
CD80 (B7-1) 7 (17.9%) 4.4 vs 2.9 0.638
CD86 (B7-2) 8 (20.5%) 2.0 vs 5.9 0.030
TBX21 2 (5.1%) 0.8 vs 4.9 0.156
Pro-inflammatory response markers
IL1B 15 (38.5%) 2.7 vs 4.9 0.884
STAT1 3 (15.4%) 6.3 vs 2.7 0.963
TNF 5 (12.8%) 1.1 vs 4.4 0.337
DDX58 12 (30.8%) 4.4 vs 2.9 0.686
MX1 8 (20.5%) 4.4 vs 2.9 0.581
CXCL10 4 (10.3%) 4.4 vs 2.9 0.814
CXCR6 6 (15.4%) 4.4 vs 2.9 0.864
Tumor infiltrating lymphocytes markers
CD2 3 (15.4%) NR vs 2.7 0.320
CD3 0 (0.0%) - vs 4.4 -
CD4 9 (23.1%) 2.4 vs 5.9 0.141
CD8 2 (5.1%) 0.9 vs 4.9 0.009
FOXP3 8 (20.5%) 4.4 vs 2.9 0.449
KLRD1 5 (12.8%) 2.0 vs 4.9 0.142
SLAMF4 4 (10.3%) 2.0 vs 4.9 0.257
CD20 1 (2.6%) 2.4 vs 4.4 0.423
Other immunotherapy markers
CD38 6 (15.4%) 4.4 vs 2.9 0.605
GATA3 5 (12.8%) 5.9 vs 2.9 0.503
Abbreviation: HR, hazard ratio; PFS, progression-free survival; NR, not reached.
All patient received anti-PD-1/PD-L1 based therapy (alone or in combination
with other agent).
*See Methods for definition of very high, high, moderate, low, very low biomar-
ker expression.
**P-values with univariate analysis by log-rank test.
***P-values significant after the Bonferroni correction. Cutoff for significant
P-values were defined as 0.05/number of markers at each section. For
example, there were 6 variables in “Other Checkpoint markers”. For this
category, significant P-values were defined as less than or equal to 0.0083
(0.05/6).
Table 4. Correlation between immune markers and clinical benefit (SD≥6m/PR/
CR) from anti-PD-1/PD-L1 based immunotherapy (N = 32).
Immune markers
SD≥6m/PR/CR (%)
High/very high * Moderate/low/very low * P-value **
Checkpoint markers
PD-1 0/1 (0.0%) 14/31 (45.2%) > 0.999
PD-L1 1/1 (100%) 13/31 (41.9%) 0.438
PD-L2 1/5 (20.0%) 13/27 (48.1%) 0.355
Other Checkpoint markers
BTLA 0/0 (0.0%) 14/32 (43.8%) -
CTLA-4 1/1 (100%) 13/31 (41.9%) 0.438
LAG3 0/1 (0.0%) 14/31 (45.2%) > 0.999
TIM3 0/5 (0.0%) 14/27 (51.9%) 0.052
VISTA 0/5 (0.0%) 14/27 (51.9%) 0.052
TNFRSF14 0/0 (0.0%) 14/32 (43.8%) -
Macrophage-associated markers
CCL2 2/7 (28.6%) 12/25 (48.0%) 0.426
CCR2 2/6 (33.3%) 12/26 (46.2%) 0.672
CD163 1/6 (16.7%) 13/26 (50.0%) 0.196
CD68 0/4 (0.0%) 14/28 (50.0%) 0.113
CSF1R 3/10 (30.0%) 11/22 (50.0%) 0.446
Metabolic immune escape markers
ADORA2A 1/2 (50.0%) 13/30 (43.3%) > 0.999
CD39 1/5 (20.0%) 13/27 (48.1%) 0.355
IDO1 1/2 (50.0%) 13/30 (43.3%) > 0.999
Anti-inflammatory response markers
IL10 0/5 (0.0%) 14/27 (51.9%) 0.052
TGFB1 1/5 (20.0%) 13/27 (48.1%) 0.355
T-cell primed markers
CD137 2/3 (66.7%) 12/29 (41.4%) 0.568
CD27 0/1 (0.0%) 14/31 (45.2%) > 0.999
CD28 0/4 (0.0%) 14/28 (50.0%) 0.113
CD40 1/2 (50.0%) 13/30 (43.3%) > 0.999
CD40 ligand 0/1 (0.0%) 14/31 (45.2%) > 0.999
GITR 5/6 (83.3%) 9/26 (34.6%) 0.064
ICOS 1/1 (100%) 13/31 (41.9%) 0.438
ICOS ligand 3/8 (37.5%) 11/24 (45.8%) > 0.999
OX40 3/3 (100%) 11/29 (37.9%) 0.073
OX40 ligand 1/7 (14.3%) 13/25 (52.0%) 0.104
GZMB 0/2 (0.0%) 14/30 (46.7%) 0.492
IFNG 0/0 (0.0%) 14/32 (43.8%) -
CD80 (B7-1) 2/5 (40.0%) 12/27 (44.4%) > 0.999
CD86 (B7-2) 0/6 (0.0%) 14/26 (53.8%) 0.024
TBX21 0/1 (0.0%) 14/31 (45.2%) > 0.999
Pro-inflammatory response markers
IL1B 5/13 (38.5%) 9/19 (47.4%) 0.725
STAT1 2/2 (100%) 12/30 (40.0%) 0.183
TNF 2/5 (40.0%) 12/27 (44.4%) > 0.999
DDX58 4/10 (40.0%) 10/22 (45.5%) > 0.999
MX1 3/7 (42.9%) 11/25 (44.0%) > 0.999
CXCL10 1/2 (50.0%) 13/30 (43.3%) > 0.999
CXCR6 1/3 (33.3%) 13/29 (44.8%) > 0.999
Tumor infiltrating lymphocytes markers
CD2 1/1 (100%) 13/31 (41.9%) 0.438
CD3 0/0 (0.0%) 14/32 (43.8%) -
CD4 1/7 (14.3%) 13/25 (52.0%) 0.104
CD8 0/2 (0.0%) 14/30 (46.7%) 0.492
FOXP3 3/6 (50.0%) 11/26 (42.3%) > 0.999
KLRD1 0/3 (0.0%) 14/29 (48.3%) 0.238
SLAMF4 0/3 (0.0%) 14/29 (48.3%) 0.238
CD20 0/1 (0.0%) 14/31 (45.2%) > 0.999
Other immunotherapy markers
CD38 3/4 (75.0%) 11/28 (39.3%) 0.295
GATA3 2/4 (50.0%) 12/28 (42.9%) > 0.999
*See Methods for definition of very high, high, moderate, low, very low biomar-
ker expression.
**P-values with univariate analysis by Fisher’s exact test; no P-values were
statistically significant after the Bonferroni correction; cutoff for significant
P-values were defined as 0.05/number of markers in each section.
Abbreviation: CR, complete response; PD, progressive disease; PR, partial
response; SD, stable disease
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validation in a larger dataset is needed. This is especially pertinent
for the clinical data, which requires a larger sample size that would
permit a multivariate analysis. Second, since the number of
patients for each cancer diagnosis was based on the number of
tests requested for cancer-immunity cycle markers by the treating
physician, there is a potential of sample size bias. Third, though the
cancer immune landscape data was collected prospectively, the
analysis of correlation with immunotherapy treatment outcome
was evaluated retrospectively. Fourth, mRNA expression does not
always correlate the protein expression. Moreover, immune mar-
kers can be expressed on both immune and tumor cells, which
may be differentiated by immunohistochemistry testing, and
requires further investigation. Fifth, dynamic changes in cancer-
immunity markers can be observed, especially with anti-cancer
therapies. In-depth analysis of the association between therapy and
immunity markers is required. Despite these limitations, the cur-
rent report provides a comprehensive analysis of cancer-immunity
cycle markers and clinical correlates in the pan-cancer setting.
In conclusion, we have investigated 101 patients with
diverse cancers and demonstrated that most patients (87.1%,
88/101) had distinct (and complex) patterns of cancer-
immunity markers. The majority of patients (99% [100/101])
had multiple potentially targetable cancer-immunity markers
(with either an FDA-approved agent [on- or off-label] or with
an agent that is in clinical investigation). Therapeutically, high
expression of the checkpoints TIM-3 and VISTA as well as the
macrophage-associated marker CD68 were associated with
significantly worse PFS after anti-PD-1/PD-L1 based immu-
notherapies. Our observations suggest that upregulation of
alternative checkpoints or myeloid suppression (via macro-
phage-associated markers) may diminish responsiveness to
anti-PD-1/PD-L1 agents. Furthermore, individualizing immu-
notherapy agents to each patient’s tumor immune portfolio
merits investigation for optimized outcomes.
Materials and methods
Patients
The cancer-immunity markers among 101 eligible consecutive
patients with diverse solid cancers seen at the University of
California San Diego Moores Cancer Center for Personalized
Therapy were examined at a Clinical Laboratory
Improvement Amendments (CLIA)-licensed and College of
American Pathologist (CAP)-accredited clinical laboratory,
OmniSeq (https://www.omniseq.com/). We used the electro-
nic medical record to curate the clinical characteristics of
these patients. All investigations followed the guidelines of
the UCSD Institutional Review Board for data collection
(Profile Related Evidence Determining Individualized Cancer
Therapy, NCT02478931) and for any investigational therapies
for which the patients consented. Among patients who had
anti-PD-1/PD-L1 based therapy (N = 39), all samples were
collected prior to the checkpoint inhibitor based therapy.
Tissue samples and analysis of cancer-immunity markers
Tumors were provided as formalin-fixed, paraffin-embedded
(FFPE) samples and evaluated with RNA sequencing by
OmniSeq laboratory. Briefly, total RNA was extracted from
FFPE by means of the truXTRAC FFPE extraction kit (Covaris,
Inc., Woburn, MA), following the manufacturer’s instructions
with some modifications. Following purification, RNA was
eluted in 50 µL water and yield was determined by the Quant-
iT RNA HS Assay (Thermo Fisher Scientific, Waltham, MA), as
per manufacturer’s recommendation. A predefined yield of 10
ng RNA was used as acceptance criteria to ensure adequate
library preparation. RNA-sequencing absolute reads were gen-
erated using Torrent Suite’s plugin immuneResponseRNA
(v5.2.0.0)34 The RNA library was prepared to measure RNA
expression of 51 targeted immune response markers including
checkpoint markers (N = 9 markers including PD-L1, PD-L2,
CTLA-4 and LAG3), macrophage-associated markers (N = 5
markers including CCR2, CD68 andCSF1R), metabolic immune
escape markers (N = 3 markers including ADORA2A and
IDO1), anti-inflammatory response markers (N = 2 markers,
IL10 and TGFB1), T-cell primed markers (N = 15 markers
including CD40, GITR, ICOS and OX40), pro-inflammatory
response markers (N = 7 markers including IL1B and TNF),
tumor infiltrating lymphocytes markers (N = 8 markers includ-
ing CD4, CD8 and FOXP3) and other immunotherapy markers
(N = 2) (Supplemental Table 1). Transcript abundance was
normalized and compared to an internal reference population
(N = 735 patients with diverse cancers) which were used to rank
RNA expression in test samples34 Rank values were set on a scale
of 1 to 100 and stratified into “Very high” (95–100), “High”
(85–94), “Moderate” (50–84), “Low” (20–49), and “Very Low”
(0–19). Tissue samples were obtained via biopsies in 54 patients
(53.5%) and via surgically resected samples in 47 patients
(46.5%). Moreover, in 50 patients (49.5%), the biopsies were
from the primary tumor and in 49 patients (48.5%) they were
from metastatic sites (N = 2 with carcinoma of unknown
primary).
Endpoints and statistical methods
Patient characteristics and the pattern of cancer-immunity
markers were summarized by descriptive statistics. The
Fisher’s exact test and the Bonferroni correction were used
for categorical variables. Response to anti-PD-1/PD-L1
based immunotherapy were assessed by imaging (e.g. com-
puted tomography and/or magnetic resonance imaging) and
categorized into progressive disease, SD, PR and CR accord-
ing to the treating physician’s evaluation (immunotherapy
response is evaluated by iRECIST criteria). PFS was defined
as time interval between the start of therapy and the date of
disease progression. Patients with ongoing therapy without
progression at the last follow up date were censored for PFS
at that date. Log-rank test and Bonferroni correction were
used to compare subgroups of patients. All tests were
2-sided and P-values ≤ 0.05 were considered significant.
Statistical analyses were performed with assistance from
coauthor RO using SPSS version 24.0 (Chicago, IL, USA).
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